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A 43 year-old white male with a history of hypertension
and a smoking history of 30 pack-years presented to the
emergency room complaining of cough, severe dyspnea,
nausea, and vomiting. Ten days prior to presentation, he
experienced flu-like symptoms with a low-grade fever,
myalgias, and malaise that lasted approximately four days
but resolved spontaneously. He had had a cough produc-
tive of white sputum and blood-tinged nasal drainage for
one week. Three days prior to presentation, he began to
experience right upper quadrant abdominal pain and bil-
ious vomiting. The patient worked as a bar inspector and
had a routine PPD check 9 months prior to presentation
which was negative. However, his daughter did have a
recent positive screening PPD with a negative chest x-ray.
On presentation, his temperature was 99.8 degrees
Fahrenheit, blood pressure was 180/96 mm/Hg, pulse
was 117 bpm, and pulse oximetry was 92% on room air.
He was admitted to Thomas Jefferson University
Hospital. On the day following admission, the patient
became more dyspnic and required increased levels of
oxygen, necessitating transfer to the medical coronary
intensive care unit. Exam at this time revealed the patient
was in moderate respiratory distress with pulse oximetry
of 95% on face mask of 50% oxygen, blood pressure of
195/105 mm/Hg, pulse of 125 bpm, and respiratory rate
of 36. Lung exam revealed scattered rales worse on the
right but no wheezing. On cardiac exam, he was tachy-
cardic but no murmurs, rubs, or gallops were heard.
Abdominal exam revealed normal bowel sounds, no
masses or distention, and no tenderness. The skin exam
revealed no rashes, and the neurologic exam was intact.
Laboratory studies revealed an elevated white blood cell
count of 12,400 ml3 with 87% neutrophils, 3% bands,
5% lymphocytes, and 5% monocytes. The hemoglobin
was slightly decreased at 12 g/dL with an MCV of 96 fL.
The platelet count was within normal limits. The patient
had a decreased sodium of 118 mmol/L, elevated potas-
sium of 5.3 mmol/L, decreased chloride of 87 mmol/L,
and decreased ionized calcium of 4.3 mg/dL. His BUN
was elevated at 39 mg/dL with an elevated creatinine of
1.3 mg/dL. Liver function tests were within normal lim-
its. Arterial blood gas obtained when dyspnea worsened
revealed a pH of 7.43, pCO2 of 38 mmHg, pO2 of 52
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mmHg, and oxygen saturation of 88% on room air. A
repeat blood gas on a 50% facemask revealed a pH of
7.3, pCO2 of 33 mmHg, and pO2 of 78 mmHg.
Urinalysis revealed 1+ ketones, 1+ protein, and 4+
blood. Chest x-ray showed bilateral interstitial infiltrates
and an echocardiogram was normal with ejection frac-
tion of 65% except for mild concentric LVH.
The patient developed a single episode of hemoptysis
with blood-tinged sputum, worsening shortness of
breath, and respiratory fatigue two days after transfer to
the intensive care unit. At this time the patient under-
went elective intubation. Also of note was that his crea-
tinine had increased from 1.2 on admission to 3.1 mg/dL
on the day of intubation. Studies for influenza titers,
urine legionella antigen, HSV, CMV, hepatitis B and C
panels, cryoglobulin, pANCA, and cANCA were sent at
that time, and later found all to be negative. Concern
over his episode of hemoptysis and rise in creatinine
prompted a workup for pulmonary-renal syndromes.
Urine microscopic exam revealed red blood cell casts, and
erythrocyte sedimentation rate was found to be elevated
at 104 mm/hr. The patient was given the presumptive
diagnosis of Goodpasture’s Syndrome and was started on
empiric plasmapheresis, cyclophosphamide, and steroids
for the worsening renal and pulmonary function. His cre-
atinine and oxygenation improved greatly with the treat-
ment, and he was able to be extubated one day after
initiation of therapy.
A renal biopsy with immunoflourescent staining was per-
formed the day after starting therapy. This demonstrated
linear staining of the glomerular basement membrane
for IgG and complement, confirming the diagnosis of
Goodpasture’s Syndrome. The patient continued to
recover and repeat chest x-ray performed 9 days after ini-
tiation of therapy demonstrated marked improvement in
his pulmonary disease. Interestingly, serum anti-GBM
antibodies remained negative, however this test has only
a 60% sensitivity.
Discussion:
Goodpasture’s Syndrome is a relatively rare syndrome.
The incidence is one case per 2 million in the Caucasian
population. The peak incidence has a mean age of 35,
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with a second peak in the 6th or 7th decades.
Interestingly, men have a 6 times greater risk of develop-
ing Goodpasture’s during their second or third decades
of life, but by the second peak the chance is equal
between men and women1. Risk factors include recent
Influenza A infection, exposure to hydrocarbons (usually
found in dry-cleaning solvents), smoking, and HLA-
DRw15 , HLA-DRw16, and HLA-DR41.
The disease occurs when the patient develops an anti-
glomerular basement membrane antibody (Anti-GBM),
which is against the C-terminus of the alpha-3 chain of
type IV collagen2. The alpha-3 chain is only found in
renal glomerular basement membranes and alveolar
basement membranes, whereas all other basement mem-
branes in the body express alpha-1 and alpha-2.
Additionally, the glomerular basement membrane is at
risk of attack due to direct contact with antibodies in
the blood through fenestrae in the glomerular endothe-
lium. The alveolar basement membrane becomes
exposed to large molecules like IgG when there is
increased permeability from non-specific lung injury
(such as smoking, Influenza A, or hydrocarbon exposure).
The antibody causes a Type II hypersensitivity reaction,
causing homogenous diffuse linear deposition of IgG
(and often C3) along the glomerular and alveolar base-
ment membranes.
Most patients with Goodpasture’s Syndrome have both
pulmonary and renal disease. These comprise 60-80% of
patients with anti-GBM disease. Twenty to 40% have
renal disease alone, and 10% have pulmonary hemor-
rhage alone3. The majority of patients have hemoptysis
at some point, and it usually precedes renal disease by
hours to months to years. In some cases, only bron-
chioalveolar lavage or biopsy can demonstrate the hem-
orrhage. Usually the initial pulmonary blood loss is
small, however massive hemoptysis can result in rapid
respiratory failure and death. Renal failure can occur
rapidly, over hours to weeks, and is described as rapidly
progressive glomerulonnephritis. Other symptoms are
non-specific. Nausea and vomiting, such as in this
patient, occurs in 41% of patients with Goodpasture’s.
Chills and fever are present in 25%, chest pain in 40%,
and 14% have weight loss3.
Diagnosing Goodpasture’s Syndrome is often a challenge
initially, but the right constellation of signs, symptoms,
and lab results will heighten suspicion. Patients with
Goodpasture’s will have a slightly elevated ESR, a fall in
hemoglobin as well as iron deficiency anemia, rising cre-
atinine with proteinuria, hematuria, and red blood cell
casts on the urinalysis. A positive Anti-GBM antibody is
usually diagnostic, however, it is a difficult test to uti-
lize. One method of determining Anti-GBM is by using
direct immunofluorescence, in which the patient’s serum
is incubated with normal renal tissue. However, this has
a 40% false negative result rate, such as seen in our
patient4. ELISA for Anti-GBM is the most sensitive and
specific, however false positives can occur if the assay is
done without utilizing purified Goodpasture antigen.
Western Blot is not widely available.  If testing is done
appropriately and yields a true positive, there is a close
correlation between antibody level and disease activity.
Renal biopsy is the definitive diagnostic procedure. Light
microscopy in early Goodpasture’s will show mesangial
expansion and hypercellularity, middle stage will show
focal segmental glomerulonephritis (GN), advanced
shows crescentic GN with widespread glomerular necro-
sis1. Immunofluorescence targeting IgG or C3 will
demonstrate a characteristic linear basement membrane
distribution. Lung biopsy is of much lower yield. Light
microscopy only shows non-specific alveolar hemorrhage,
and immunofluorescence only occasionally shows linear
staining of lung tissue. 
Untreated, the clinical course is grave. The renal failure
rapidly progresses from mild renal insufficiency to end-
stage, and oliguria is a poor prognosticator. However, it
is the pulmonary hemorrhage which is the primary cause
of death in these patients. Surprisingly, the amount of
hemoptysis does not correlate to degree of alveolar hem-
orrhage. Successful treatment will usually leave no resid-
ual pulmonary deficit or fibrosis.
Treatment goals encompass two arms; firstly, remove cur-
rently circulating antibodies (done through daily plasma-
pheresis for 2 weeks), and secondly, prevent further
production of antibodies (utilizing immunosuppressives,
such as cyclophosphamide and steroids for 6 months).
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reasonable suspicion of Goodpasture’s, and before end-
stage damage occurs. Anti-GBM antibody tests and
biopsy results will take too long to become available, and
the serum antibody may have a false negative. Even
aggressive treatment usually does not improve severe
renal failure, and with a creatinine >6 mg/dL and no pul-
monary involvement, treatment risks outweigh the bene-
fits. Recurrence is rare if the patient is adequately treated
for 6 months.
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